Orexigen Therapeutics, Inc.
NASDAQ: OREX
$0.22
Closing price April 3, 2018
Orexigen, Advaxis, Globalstar, and Piedmont Office Realty Trust all posted new 52-week lows Tuesday.
Published:
Last Updated:
Anthera Pharmaceuticals, Orexigen Therapuetics, VEON, and New Gold all posted new 52-week lows Monday.
Published:
Last Updated:
A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving more credence to the Trump rally and positive sentiment for the health care...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 16, include Chipotle Mexican Grill, Oracle, Orexigen Therapeutics, PulteGroup, Reynolds American and Valeant...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday, February 29, include Huntington Bancshares, Nucor, Orexigen Therapeutics, SanDisk, Square and VIVUS.
Published:
Last Updated:
Orexigen Therapeutics has announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals.
Published:
Orexigen Therapeutics shares plunge after termination of cardiovascular outcomes study of the obesity drug Contrave.
Published:
The last full week of March was choppy and took away most of the 2015 gains for the Dow and the S&P. Still, investors keep looking for value.
Published:
Looking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech sector can...
Published:
Last Updated:
Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.
Published:
A new report from Merrill Lynch highlights five biotechs that have been absolutely crushed but have outstanding potential and catalysts that can drive them much higher.
Published:
Many investors believe stocks priced under $10 have much more upside than traditional Dow and S&P 500 stocks.
Published:
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Published:
Stocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the bull market has...
Published:
These are the three analysts stock picks from Wall Street in recent days that were projected to have implied upside of 100% or more.
Published: